Biotechnology

TRANSTHERA-B

Akeso Places 3.83 Million New H Shares to Raise Over 150 Million HKD for Core Product Development

Pharmaron Announces Clinical Results of Tenegitinib Combined with Atezolizumab for Advanced Solid Tumors

YjHK-B Completes Rights Issue at HKD 57.03 for 5,085,000 Shares

Pharmaron-B Completes First Patient Dosing for Tinengotinib in III Phase Clinical Trial for Advanced Bile Duct Cancer

YJHK plans to issue 5,085,000 new H shares at HKD 57.03 per share

TRANSTHERA-B released FY2025 Q3 earnings on March 31, 2026 (BJT), with actual revenue of HKD 0 and EPS of HKD -0.2382

TRANSTHERA-B released FY2025 9 Months Earnings on March 31, 2026 (BJT), with actual revenue of HKD 0 and EPS of HKD -0.5863

TRANSTHERA-B released FY2025 earnings on March 31 After-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.8306

TRANSTHERA-B released FY2025 Q4 earnings on March 31 After-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.2423

TRANSTHERA-B to Release FY2025 Annual Earnings on March 31, 2026 After-Market (BJT)

Pharmaron-B Completes Placing of 2.1 Million Shares Raising HKD 190 Million

Pharmaron-B to Raise Funds Through Placing 2.1 Million Shares at HKD 92.85 for R&D

YjAnk Pharma Announces Phase II Clinical Trial Data for Tienicetinib in Advanced Biliary Tract Cancer

Pharmaron-B's New Drug Tengnotinib Application for Market Approval Accepted by CDE

Core product Tengatinib of Yaji Kangang-B publishes exploratory clinical 2 phase results for bile duct cancer

Juventure's Tegavivint receives priority review from NMPA

Yaoke Technology sees significant increase in per share net assets in Q3, secretary explains reasons

Yaojie Health Care Grants Global Development Rights to NLRP3 Inhibitor for $881.5 Million

Jiangke-B Enters into NLRP3 Inhibitor Collaboration Agreement with Neurocrine

Yj-Ak-B's Core Product Combination Therapy Receives NMPA Conditional Clinical Approval

FAMEGLOW

NEW GONOW RV

REALWAY CAPITAL

TJCD

ZXZN QI-HOUSE

51WORLD

ZHONGSHENJIANYE

CENTRAL DEV H

HAICHANG HLDG

JOLIMARK

02617

TRANSTHERA-Bannounced the placing of 3.836 million new H shares at HKD40.83 each, an 18% discount to the previous closing price of HKD49.8. The net proceeds of approximately HKD152 million will primarily fund the development of new indications for Tinegotinib, with 10% allocated for working capital and general corporate purposes.

AASTOCKS News

TRANSTHERA-B  Places Shares at 18% Discount, Net Proceeds HKD152 million

02656

02706

06660

00580

02865

02477

00259

00596

02940

160 HEALTH(02656) rose 44.26%, with a trading turnover 2.4 Billion HKD, and a year-to-date fell 57.9%. HAIZHI TECH GP(02706) rose 25.96%, with a trading turnover 363.0 Million HKD, and a year-to-date rose 129.5%. AIM VACCINE(06660) rose 21.83%, with a trading turnover 10.6 Million HKD, and a year-to-date fell 4.4%.

Top Gainers&Losers

160 HEALTH

HAIZHI TECH GP

AIM VACCINE

SUN.KING TECH

DRINDA

WELLCELL HOLD

YEEBO (INT'L H)

INSPUR DIGI ENT

Top 10 HK Stock Gainers (5.8)

TRANSTHERA-B rose 18.76%; BeiGene rose 1.22%, with a transaction volume of HKD 775 million; CanSino Biologics fell 2.32%, with a transaction volume of HKD 472 million; Innovent Biologics fell 2.31%, with a transaction volume of HKD 456 million; Kelun-Biotech fell 0.92%, with a market capitalization of HKD 105.1 billion

HK Stock Alerts

BEONE MEDICINES

AKESO

INNOVENT BIO

SKB BIO

Hong Kong stock movement: TRANSTHERA-B rose 18.76%, with clear capital flow, market sentiment triggered volatility attention

Yaojie Ankang-Bexperienced a significant rise in the Hong Kong stock market, with shares increasing by more than 21.7%. According to Jin10, the stock showed strong performance during the trading session.

CoinLive

Hong Kong Stock: Yaojie Ankang-B Surges Over 21.7%

513120

520880

159506

159992

520500

159892

520690

159316

159570

TransThera Sciences (Nanjing), Inc. has raised approximately HK$282 million through the placement of 5,085,000 new H shares at HK$57.03 each. The funds will primarily support research and development, with 57% allocated to advancing its oncology drug Tinengotinib, 33% for manufacturing and commercialization in China, and 10% for working capital. This move aims to broaden the investor base while modestly diluting existing shareholders. TransThera focuses on innovative oncology therapies and is also developing pipeline candidates like TT-00973.

Tip Ranks

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push

TRANSTHERA-B announced that the company's core product Tinengotinib (TT-00420) has completed the first patient dosing in a confirmatory Phase III clinical study for the treatment of advanced cholangiocarcinoma. Tinengotinib is an innovative multi-target small molecule kinase inhibitor developed in-house and is currently in the new drug application stage, exerting anti-tumor effects by targeting tumor cells and improving the tumor microenvironment

AASTOCKS

TRANSTHERA has completed the first patient dosing in the Phase III clinical study of Engeletinib

513700

TransThera Sciences (Nanjing), Inc. has announced a discounted placement of 5,085,000 new H shares at HK$57.03 each, representing about 1.27% of its existing share capital. The placement, which is expected to raise approximately HK$290 million, reflects an 18% discount to the last closing price. The shares will be issued to at least six professional or institutional investors under the company's existing mandate. Completion of the transaction is subject to conditions under the placing agreement.

Penghua CSI HK Connect Health Care Composite ETF

TransThera Sciences Launches Discounted HK$290 Million H-Share Placement

159748

TransThera Sciences (Nanjing), Inc. plans to implement an H Share Award Scheme to enhance equity incentives for employees and service providers. This initiative requires shareholder approval and aims to improve talent retention and align stakeholder interests. The company will appoint a Scheme Administrator for operational matters and will issue a circular with more details. Shareholders are advised to exercise caution until the scheme is approved. TransThera Sciences is listed on the Hong Kong Stock Exchange under stock code 2617, focusing on biopharmaceutical innovations.

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TransThera Sciences Proposes New H Share Award Scheme to Boost Equity Incentives

562050

TRANSTHERA-B announced its 2025 annual performance, reporting a loss of 296 million RMB (the same below), compared to a loss of 275 million RMB in the previous year; the loss per share is 0.76 RMB. No dividend is declared. No revenue was generated during the year

TRANSTHERA-B(02617.HK)

TRANSTHERA-B Places Shares at 18% Discount, Net Proceeds HKD152 million